Search

Your search keyword '"Vincenzo Brescia Morra"' showing total 9 results
Start Over Author "Vincenzo Brescia Morra" Journal journal of the neurological sciences
9 results on '"Vincenzo Brescia Morra"'

1. Monoclonal antibodies for mild-to-moderate COVID-19 in multiple sclerosis: A case series

Author

Marcello Moccia, Antonio Riccardo Buonomo, Riccardo Scotto, Giulio Viceconte, Mariano Nobile, Roberta Lanzillo, Vincenzo Brescia Morra, Ivan Gentile, Moccia, Marcello, Buonomo, Antonio Riccardo, Scotto, Riccardo, Viceconte, Giulio, Nobile, Mariano, Lanzillo, Roberta, Brescia Morra, Vincenzo, and Gentile, Ivan

Subjects
Treatment, COVID-19 Vaccines, Multiple Sclerosis, Monoclonal antibodie, Neurology, Antibodies, Monoclonal, Humans, COVID-19, Multiple sclerosi, Neurology (clinical), Antibodies, Viral
Abstract

We reported on five people with MS, using immunodepleting disease modifying treatments (anti-CD20 monoclonal antibodies and sphingosine-one-phosphate modulators) and with reduced COVID-19 vaccine response, who had mild-to-moderate symptomatic COVID-19, and were treated with anti-SARS-CoV-2 monoclonal antibodies. In particular, we showed the possibility to use monoclonal antibodies to speed-up recovery from COVID-19 in MS, in the absence of any COVID-19 residuals or MS changes (e.g., relapses or disability).

Published
2022

2. Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients

Author

Roberto Bergamaschi, Damiano Paolicelli, Davide Mainome, F Caputo, Valentina Torri Clerici, Pietro Iaffaldano, Rocco Totaro, Mauro Zaffaroni, Paolo Bellantonio, Claudio Gasperini, Giancarlo Comi, Giuseppe Lucisano, Eleonora Cocco, Patrizia Sola, Giacomo Lus, Massimo Filippi, Marco Salvetti, Maria Trojano, Franco Granella, Marco Capobianco, Antonella Conte, Vincenzo Brescia Morra, Marco Rovaris, Francesco Patti, Giovanna De Luca, Maria Pia Amato, Carlo Pozzilli, Giorgia Teresa Maniscalco, Matilde Inglese, and Giuseppe Salemi

Subjects
medicine.medical_specialty, Neurology, business.industry, Multiple sclerosis, medicine, Treatment strategy, Neurology (clinical), Long term disability, Intensive care medicine, business, medicine.disease
Published
2021

3. Retinal and choriocapillary vascular changes in early stages of multiple sclerosis: A prospective study

Author

Antonio Luca Spiezia, Roberta Lanzillo, Maria Petracca, Gilda Cennamo, Anna Lamberti, Daniela Montorio, Antonio Carotenuto, Marcello Moccia, Vincenzo Brescia Morra, and Chiara Criscuolo

Subjects
medicine.medical_specialty, chemistry.chemical_compound, Neurology, chemistry, business.industry, Ophthalmology, Multiple sclerosis, Medicine, Retinal, Neurology (clinical), business, medicine.disease, Prospective cohort study
Published
2021

4. Ocrelizumab treatment in multiple sclerosis: Prospective real world observational multi-center study in Campania, Italy

Author

Vincenzo Brescia Morra, Leonardo Sinisi, Marcello Moccia, Rosa Iodice, Roberta Lanzillo, Gioacchino Tedeschi, Giacomo Lus, Simona Bonavita, Giuseppina Miele, Fratta Mario, Alvino Bisecco, Giorgia Teresa Maniscalco, Maria Petracca, Romano Felice, Raffaele Dubbioso, Maria Di Gregorio, Antonio Luca Spiezia, Nicola Capasso, Elisabetta Signoriello, and Antonio Carotenuto

Subjects
medicine.medical_specialty, Neurology, business.industry, Multiple sclerosis, Multi center study, Medicine, Observational study, Ocrelizumab, Medical physics, Neurology (clinical), business, medicine.disease, medicine.drug
Published
2021

5. Long-term disability progression in childhood and adolescent onset multiple sclerosis patients

Author

Mattia Fonderico, Alessandra Lugaresi, Maria Trojano, Franco Granella, Davide Maimone, Antonio Bertolotto, Paola Cavalla, Eleonora Cocco, Giacomo Lus, Vincenzo Brescia Morra, Marco Rovaris, Maria Pia Amato, Patrizia Sola, Paolo Confalonieri, Giuseppe Salemi, Marta Simone, Paola Valentino, Francesco Patti, Marco Onofrj, Ermelinda De Meo, Roberto Bergamaschi, Massimo Filippi, Giorgia Teresa Maniscalco, Ilaria Pesci, and Raffaello Bonacchi

Subjects
Pediatrics, medicine.medical_specialty, Adolescent onset, Neurology, business.industry, Multiple sclerosis, medicine, Neurology (clinical), Long term disability, medicine.disease, business
Published
2021

6. Clinical relevance of atrophy, myelin and iron brain microstructural alterations in multiple sclerosis: A multi-parameter MRI study

Author

Mario Quarantelli, Andrea Elefante, Giuseppe Pontillo, Sirio Cocozza, Maria Petracca, Vincenzo Brescia Morra, Roberta Lanzillo, Teresa Costabile, Arturo Brunetti, Serena Monti, Giuseppe Palma, Fabio Tortora, and Antonio Carotenuto

Subjects
Pathology, medicine.medical_specialty, business.industry, Multiple sclerosis, medicine.disease, Myelin, Atrophy, medicine.anatomical_structure, Neurology, Medicine, Clinical significance, Neurology (clinical), business, Multi parameter
Published
2021

7. Progression independent of relapse activity in early multiple sclerosis patients

Author

Franco Di Palma, Angelo Bellinvia, Marta Simone, Eleonora Cocco, Vito Lepore, Lorenzo Razzolini, Paola Valentino, Maria Pia Amato, Francesco Patti, Massimo Filippi, Daniele Spitaleri, Pietro Iaffaldano, Luisa Pastò, Rocco Totaro, Davide Maimone, Giacomo Lus, A. Protti, Ilaria Pesci, Patrizia Sola, Marco Onofrj, Mattia Fonderico, Alessandra Lugaresi, Roberto Bergamaschi, Giorgia Teresa Maniscalco, M. Vianello, Vincenzo Brescia Morra, Maria Trojano, Franco Granella, Emilio Portaccio, Paolo Confalonieri, Umberto Aguglia, and Giuseppe Salemi

Subjects
Oncology, medicine.medical_specialty, Neurology, business.industry, Internal medicine, Multiple sclerosis, medicine, Neurology (clinical), medicine.disease, business
Published
2021

8. Cardiovascular risk is associated with verbal learning dysfunction in multiple sclerosis

Author

Marcello Moccia, Teresa Costabile, Giuseppe Servillo, Fabrizia Falco, Antonio Carotenuto, Antonio Reia, Vincenzo Brescia Morra, Matteo Conenna, Maria Petracca, Martina Petruzzo, and Roberta Lanzillo

Subjects
Neurology, business.industry, Multiple sclerosis, medicine, Neurology (clinical), medicine.disease, Verbal learning, business, Clinical psychology
Published
2021

9. Neuropsychological assessment, quantitative MRI and ApoE gene polymorphisms in a series of MS patients treated with IFN beta-1b

Author

Vittorio Schiavone, Roberta Lanzillo, Elena Salvatore, Giovanni Coppola, Mario Muto, Ciro Florio, Bruno Alfano, Vincenzo Bonavita, Giuseppe Orefice, V. Scarano, Raffaele Liuzzi, Arturo Brunetti, Anna Prinster, Vincenzo Brescia Morra, Lanzillo, Roberta, Prinster, A, Scarano, V, Liuzzi, Raffaele, Coppola, G, Florio, C, Salvatore, Elena, Schiavone, V, Brunetti, Arturo, Muto, M, Orefice, Giuseppe, Alfano, B, Bonavita, Vincenzo, and BRESCIA MORRA, Vincenzo

Subjects
Adult, Male, medicine.medical_specialty, Pathology, Longitudinal study, Multiple Sclerosis, Adolescent, Neuropsychological Tests, Statistics, Nonparametric, Central nervous system disease, Apolipoproteins E, Internal medicine, medicine, Humans, Effects of sleep deprivation on cognitive performance, Neuropsychological assessment, Cognitive deficit, Polymorphism, Genetic, medicine.diagnostic_test, Multiple sclerosis, Cognitive disorder, Neuropsychology, Interferon-beta, Middle Aged, medicine.disease, Magnetic Resonance Imaging, Neurology, Female, Neurology (clinical), medicine.symptom, Psychology, Follow-Up Studies, Interferon beta-1b
Abstract

Few trials issued the effect of disease-modifying medications on cognitive functions in multiple sclerosis. We designed an open-label longitudinal study to evaluate, during 2 years, cognitive performance and its relationship with MRI data and ApoE polymorphism findings in a group of relapsing-remitting (R-R) multiple sclerosis (MS) Interferon (IFN) beta-1b-treated patients (median age 30 years, median disease duration 3.4 years). Complete neuropsychological battery was grouped into attention, information learning/memory, language and visuospatial functions. Fifty-two patients (33 females) were enrolled in the study. Six patients (11.5%) dropped out, mainly due to side effects. At baseline neuropsychological evaluation, we found 54% normal, 42% mildly impaired and 4% moderately impaired patients. At 2 years follow-up, cognitive status was stable in 65%, improved in 33% and worsened in 2% of patients. No significant relations were found between global cognitive outcome vs. EDSS change, clinical disease activity, MRI data or ApoE gene polymorphisms over the 2 years follow-up. EDSS and MRI fractional volumes were found to correlate with the performance at single tests. Twenty-one patients (45.6%) showed active MRI scans throughout the study, without any worsening at the corresponding neuropsychological examination. This ongoing trial suggests a possible beneficial effect of IFN beta-1b treatment on cognitive functions in RRMS patients. Extension of follow-up and further data analyses are needed to confirm and clarify these findings. (c) 2006 Elsevier B.V. All rights reserved.

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results